Why Use Nutraceutical Strategies for the Irritable Bowel Syndrome?

Flavia       di Michele
doi:10.2174/0929867328666210917115255
Abstract

Irritable bowel syndrome (IBS) is a chronic functional bowel disorder, often stress-related, identified by many abdominal symptoms, the most important of which is chronic visceral abdominal pain. Therefore, IBS commonly impairs the quality of life of patients, moreover, it is frequently linked to depressive and anxiety symptoms. The treatment of IBS primarily focuses on symptoms relief. Unfortunately, up to now, no efficacious therapies have been found. Therefore, it would be important to develop new anti- IBS interventions.
The aim of this brief review is to summarize the current evidence of nutraceutical supplementation in IBS treatment, with probiotics, prebiotics, synbiotics, butyrate, palmitoylethanolamide and colostrum. Since nutraceutics are over-the-counter products, the review has the purpose to better inform the medicinal chemist and the practitioner about the possible beneficial mechanisms and the many advantages that these therapies offer. All of these compounds present multiple mechanisms of action, such as restoring the physiological microbiota, potentiating gastrointestinal barrier’s function, immunomodulatory, anti-inflammatory and antinociceptive activities.
From the literature data, it results that these compounds are not only capable of improving IBS symptomatology, but mainly display an optimal safety and tolerability profile.
Although extensive studies must be carried out to reinforce the evidence from the so far limited clinical trials, the supplementation with these compounds may be useful considering the warnings of prescription medicines for special populations of patients, such as elders, youngsters, or patients who need combination therapy. Finally, the nutraceutical approach may improve adherence to treatment, given its better acceptance by the patients compared to pharmacological therapy.
Keywords: IBS, nutraceutics, probiotics, prebiotics, synbiotics, butyrate, palmitoylethanolamide and colostrum.
« Previous Next »
[1] 
Lovell, R.M.; Ford, A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol.,  2012, 10(7), 712-721.e4.
[http://dx.doi.org/10.1016/j.cgh.2012.02.029] [PMID:  22426087] 
[2] 
Moloney, R.D.; Johnson, A.C.; O’Mahony, S.M.; Dinan, T.G.; Greenwood-Van Meerveld, B.; Cryan, J.F. Stress and the microbiota-gut-brain axis in visceral pain: relevance to irritable bowel syndrome. CNS Neurosci. Ther.,  2016, 22(2), 102-117.
[http://dx.doi.org/10.1111/cns.12490] [PMID:  26662472] 
[3] 
Bhattarai, Y.; Muniz Pedrogo, D.A.; Kashyap, P.C. Irritable bowel syndrome: A gut microbiota-related disorder? Am. J. Physiol. Gastrointest. Liver Physiol.,  2017, 312(1), G52-G62.
[http://dx.doi.org/10.1152/ajpgi.00338.2016] [PMID:  27881403] 
[4] 
Moalem, G.; Tracey, D.J. Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Brain Res. Rev.,  2006, 51(2), 240-264.
[http://dx.doi.org/10.1016/j.brainresrev.2005.11.004] [PMID:  16388853] 
[5] 
Greenwood-Van Meerveld, B.; Johnson, A.C. Stress-induced chronic visceral pain of gastrointestinal origin. Front. Syst. Neurosci.,  2017, 11, 86.
[http://dx.doi.org/10.3389/fnsys.2017.00086] [PMID:  29213232] 
[6] 
Späth, M. Current experience with 5-HT3 receptor antagonists in fibromyalgia. Rheum. Dis. Clin. North Am.,  2002, 28(2), 319-328.
[http://dx.doi.org/10.1016/S0889-857X(01)00014-X] [PMID:  12122920] 
[7] 
Jenkins, T.A.; Nguyen, J.C.; Polglaze, K.E.; Bertrand, P.P. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain Axis. Nutrients,  2016, 8(1), 877-884.
[http://dx.doi.org/10.3390/nu8010056] [PMID:  26805875] 
[8] 
Fond, G.; Loundou, A.; Hamdani, N.; Boukouaci, W.; Dargel, A.; Oliveira, J.; Roger, M.; Tamouza, R.; Leboyer, M.; Boyer, L. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci.,  2014, 264(8), 651-660.
[http://dx.doi.org/10.1007/s00406-014-0502-z] [PMID:  24705634] 
[9] 
Marger, F.; Gelot, A.; Alloui, A.; Matricon, J.; Ferrer, J.F.; Barrère, C.; Pizzoccaro, A.; Muller, E.; Nargeot, J.; Snutch, T.P.; Eschalier, A.; Bourinet, E.; Ardid, D. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc. Natl. Acad. Sci. USA,  2011, 108(27), 11268-11273.
[http://dx.doi.org/10.1073/pnas.1100869108] [PMID:  21690417] 
[10] 
Stilling, R.M.; Dinan, T.G.; Cryan, J.F. Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis. Genes Brain Behav.,  2014, 13(1), 69-86.
[http://dx.doi.org/10.1111/gbb.12109] [PMID:  24286462] 
[11] 
Sun, M.F.; Shen, Y.Q. Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s Disease. Ageing Res. Rev.,  2018, 45, 53-61.
[http://dx.doi.org/10.1016/j.arr.2018.04.004] [PMID:  29705121] 
[12] 
Ford, A.C.; Brandt, L.J.; Young, C.; Chey, W.D.; Foxx-Orenstein, A.E.; Moayyedi, P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol.,  2009, 104(7), 1831-1843.
[http://dx.doi.org/10.1038/ajg.2009.223] [PMID:  19471254] 
[13] 
Binienda, A.; Storr, M.; Fichna, J.; Salaga, M. Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review. Curr. Drug Targets,  2018, 19(15), 1774-1781.
[http://dx.doi.org/10.2174/1389450119666171227225408] [PMID:  29284389] 
[14] 
Sikander, A.; Rana, S.V.; Prasad, K.K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin. Chim. Acta,  2009, 403(1-2), 47-55.
[http://dx.doi.org/10.1016/j.cca.2009.01.028] [PMID:  19361459] 
[15] 
Gershon, M.D. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J. Clin. Gastroenterol.,  2005, 39(5)(Suppl. 3), S184-S193.
[http://dx.doi.org/10.1097/01.mcg.0000156403.37240.30] [PMID:  15798484] 
[16] 
Friedrich, M.; Grady, S.E.; Wall, G.C. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin. Ther.,  2010, 32(7), 1221-1233.
[http://dx.doi.org/10.1016/j.clinthera.2010.07.002] [PMID:  20678672] 
[17] 
Jembrek, M.J.; Auteri, M.; Serio, R.; Vlainic, J. GABAergic system in action: connection to gastrointestinal stress-related disorders. Curr. Pharm. Des.,  2017, 23(27), 4003-4011.
[http://dx.doi.org/10.2174/1381612823666170209155753] [PMID:  28190395] 
[18] 
Chen, L.; Ilham, S.J.; Feng, B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth. Pain Med.,  2017, 7(2) ,e42747
[http://dx.doi.org/10.5812/aapm.42747] 
[19] 
Videlock, E.J.; Shih, W.; Adeyemo, M.; Mahurkar-Joshi, S.; Presson, A.P.; Polytarchou, C.; Alberto, M.; Iliopoulos, D.; Mayer, E.A.; Chang, L. The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. Psychoneuroendocrinol,  2016, 69, 67-76.
[http://dx.doi.org/10.1016/j.psyneuen.2016.03.016] [PMID:  27038676] 
[20] 
Ford, A.C.; Harris, L.A.; Lacy, B.E.; Quigley, E.M.M.; Moayyedi, P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther.,  2018, 48(10), 1044-1060.
[http://dx.doi.org/10.1111/apt.15001] [PMID:  30294792] 
[21] 
Grundmann, O.; Yoon, S.L. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J. Gastroenterol.,  2014, 20(2), 346-362.
[http://dx.doi.org/10.3748/wjg.v20.i2.346] [PMID:  24574705] 
[22] 
Sears, C.L. A dynamic partnership: celebrating our gut flora. Anaerobe,  2005, 11(5), 247-251.
[http://dx.doi.org/10.1016/j.anaerobe.2005.05.001] [PMID:  16701579] 
[23] 
Beaugerie, L.; Petit, J.C. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract. Res. Clin. Gastroenterol.,  2004, 18(2), 337-352.
[http://dx.doi.org/10.1016/j.bpg.2003.10.002] [PMID:  15123074] 
[24] 
Dusko Ehrlich, S. MetaHIT consortium. Metagenomics of the intestinal microbiota: potential applications. Gastroenterol. Clin. Biol.,  2010, 34(Suppl. 1), S23-S28.
[http://dx.doi.org/10.1016/S0399-8320(10)70017-8] [PMID:  20889001] 
[25] 
Tuddenham, S.; Sears, C.L. The intestinal microbiome and health. Curr. Opin. Infect. Dis.,  2015, 28(5), 464-470.
[http://dx.doi.org/10.1097/QCO.0000000000000196] [PMID:  26237547] 
[26] 
Shi, N.; Li, N.; Duan, X.; Niu, H. Interaction between the gut microbiome and mucosal immune system. Mil. Med. Res.,  2017, 4, 14.
[http://dx.doi.org/10.1186/s40779-017-0122-9] [PMID:  28465831] 
[27] 
Mittal, R.; Debs, L.H.; Patel, A.P.; Nguyen, D.; Patel, K.; O’Connor, G.; Grati, M.; Mittal, J.; Yan, D.; Eshraghi, A.A.; Deo, S.K.; Daunert, S.; Liu, X.Z. Neurotransmitters: the critical modulators regulating gut-brain axis. J. Cell. Physiol.,  2017, 232(9), 2359-2372.
[http://dx.doi.org/10.1002/jcp.25518] [PMID:  27512962] 
[28] 
Collins, S.M. A role for the gut microbiota in IBS. Nat. Rev. Gastroenterol. Hepatol.,  2014, 11(8), 497-505.
[http://dx.doi.org/10.1038/nrgastro.2014.40] [PMID:  24751910] 
[29] 
Ishaque, S.M.; Khosruzzaman, S.M.; Ahmed, D.S.; Sah, M.P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol.,  2018, 18(1), 71.
[http://dx.doi.org/10.1186/s12876-018-0788-9] [PMID:  29801486] 
[30] 
Verna, E.C.; Lucak, S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap. Adv. Gastroenterol.,  2010, 3(5), 307-319.
[http://dx.doi.org/10.1177/1756283X10373814] [PMID:  21180611] 
[31] 
Ghoshal, U.C.; Shukla, R.; Ghoshal, U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver,  2017, 11(2), 196-208.
[http://dx.doi.org/10.5009/gnl16126] [PMID:  28274108] 
[32] 
Didari, T.; Mozaffari, S.; Nikfar, S.; Abdollahi, M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J. Gastroenterol.,  2015, 21(10), 3072-3084.
[http://dx.doi.org/10.3748/wjg.v21.i10.3072] [PMID:  25780308] 
[33] 
Halpern, G.M.; Prindiville, T.; Blankenburg, M.; Hsia, T.; Gershwin, M.E. Treatment of irritable bowel syndrome with Lacteol Fort: A randomized, double-blind, cross-over trial. Am. J. Gastroenterol.,  1996, 91(8), 1579-1585.
[PMID:  8759665] 
[34] 
Niedzielin, K.; Kordecki, H.; Birkenfeld, B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol.,  2001, 13(10), 1143-1147.
[http://dx.doi.org/10.1097/00042737-200110000-00004] [PMID:  11711768] 
[35] 
Nobaek, S.; Johansson, M.L.; Molin, G.; Ahrné, S.; Jeppsson, B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol.,  2000, 95(5), 1231-1238.
[http://dx.doi.org/10.1111/j.1572-0241.2000.02015.x] [PMID:  10811333] 
[36] 
Ducrotté, P.; Sawant, P.; Jayanthi, V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J. Gastroenterol.,  2012, 18(30), 4012-4018.
[http://dx.doi.org/10.3748/wjg.v18.i30.4012] [PMID:  22912552] 
[37] 
O’Sullivan, M.A.; O’Morain, C.A. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig. Liver Dis.,  2000, 32(4), 294-301.
[http://dx.doi.org/10.1016/S1590-8658(00)80021-3] [PMID:  11515626] 
[38] 
Pena, J.A.; Versalovic, J. Lactobacillus Rhamnosus GG decreases TNFa production in macrophages by contact independent mechanisms. Cell. Microbiol.,  2003, 5, 277-285.
[http://dx.doi.org/10.1046/j.1462-5822.2003.t01-1-00275.x] [PMID:  12675685] 
[39] 
Kankainen, M.; Paulin, L.; Tynkkynen, S.; von Ossowski, I.; Reunanen, J.; Partanen, P.; Satokari, R.; Vesterlund, S.; Hendrickx, A.P.; Lebeer, S.; De Keersmaecker, S.C.; Vanderleyden, J.; Hämäläinen, T.; Laukkanen, S.; Salovuori, N.; Ritari, J.; Alatalo, E.; Korpela, R.; Mattila-Sandholm, T.; Lassig, A.; Hatakka, K.; Kinnunen, K.T.; Karjalainen, H.; Saxelin, M.; Laakso, K.; Surakka, A.; Palva, A.; Salusjärvi, T.; Auvinen, P.; de Vos, W.M. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human- mucus binding protein. Proc. Natl. Acad. Sci. USA,  2009, 106(40), 17193-17198.
[http://dx.doi.org/10.1073/pnas.0908876106] [PMID:  19805152] 
[40] 
Pineton de Chambrun, G.; Neut, C.; Chau, A.; Cazaubiel, M.; Pelerin, F.; Justen, P.; Desreumaux, P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis.,  2015, 47(2), 119-124.
[http://dx.doi.org/10.1016/j.dld.2014.11.007] [PMID:  25488056] 
[41] 
Lyra, A.; Hillilä, M.; Huttunen, T.; Männikkö, S.; Taalikka, M.; Tennilä, J.; Tarpila, A.; Lahtinen, S.; Ouwehand, A.C.; Veijola, L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J. Gastroenterol.,  2016, 22(48), 10631-10642.
[http://dx.doi.org/10.3748/wjg.v22.i48.10631] [PMID:  28082816] 
[42] 
Majeed, M.; Nagabhushanam, K.; Natarajan, S.; Sivakumar, A.; Ali, F.; Pande, A.; Majeed, S.; Karri, S.K. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: A double blind randomized placebo controlled pilot clinical study. Nutr. J.,  2016, 15, 21.
[http://dx.doi.org/10.1186/s12937-016-0140-6] [PMID:  26922379] 
[43] 
Pinto-Sanchez, M.I.; Hall, G.B.; Ghajar, K.; Nardelli, A.; Bolino, C.; Lau, J.T.; Martin, F.P.; Cominetti, O.; Welsh, C.; Rieder, A.; Traynor, J.; Gregory, C.; De Palma, G.; Pigrau, M.; Ford, A.C.; Macri, J.; Berger, B.; Bergonzelli, G.; Surette, M.G.; Collins, S.M.; Moayyedi, P.; Bercik, P. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology,  2017, 153(2), 448-459.e8.
[http://dx.doi.org/10.1053/j.gastro.2017.05.003] [PMID:  28483500] 
[44] 
Dale, H.F.; Rasmussen, S.H.; Asiller, O.O.; Lied, G.A. Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients,  2019, 11(9), 2048.
[http://dx.doi.org/10.3390/nu11092048] [PMID:  31480656] 
[45] 
Staudacher, H.M.; Whelan, K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc. Nutr. Soc.,  2016, 75(3), 306-318.
[http://dx.doi.org/10.1017/S0029665116000021] [PMID:  26908093] 
[46] 
Conlon, M.A.; Bird, A.R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients,  2014, 7(1), 17-44.
[http://dx.doi.org/10.3390/nu7010017] [PMID:  25545101] 
[47] 
Quigley, E.M.M. The enteric microbiota in the pathogenesis and management of constipation. Best Pract. Res. Clin. Gastroenterol.,  2011, 25(1), 119-126.
[http://dx.doi.org/10.1016/j.bpg.2011.01.003] [PMID:  21382583] 
[48] 
Matt, S.M.; Allen, J.M.; Lawson, M.A.; Mailing, L.J.; Woods, J.A.; Johnson, R.W. butyrate and dietary soluble fiber improve neuroinflammation associated with aging in mice. Front. Immunol.,  2018, 9, 1832-1834.
[http://dx.doi.org/10.3389/fimmu.2018.01832] [PMID:  30154787] 
[49] 
Varjú, P.; Farkas, N.; Hegyi, P.; Garami, A.; Szabó, I.; Illés, A.; Solymár, M.; Vincze, Á.; Balaskó, M.; Pár, G.; Bajor, J.; Szűcs, Á.; Huszár, O.; Pécsi, D.; Czimmer, J. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: A meta-analysis of clinical studies. PLoS One,  2017, 12(8) ,e0182942
[http://dx.doi.org/10.1371/journal.pone.0182942] [PMID:  28806407] 
[50] 
Pedersen, N.; Vegh, Z.; Burisch, J.; Jensen, L.; Ankersen, D.V.; Felding, M.; Andersen, N.N.; Munkholm, P. Ehealth monitoring in irritable bowel syndrome patients treated with low fermentable oligo-, di-, mono-saccharides and polyols diet. World J. Gastroenterol.,  2014, 20(21), 6680-6684.
[http://dx.doi.org/10.3748/wjg.v20.i21.6680] [PMID:  24914395] 
[51] 
McIntosh, K.; Reed, D.E.; Schneider, T. FODMAPs alter symptoms and the metabolome of patients with IBS: Arandomised controlled trial; Gut. Published Online First, 2016. 14. 
[http://dx.doi.org/10.1136/gutjnl-2015-311339] [PMID:  26976734] 
[52] 
Tana, C.; Umesaki, Y.; Imaoka, A. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil.,  2010, 22(5), 512-519.
[53] 
Mazzawi, T.; Hausken, T.; Gundersen, D.; El-Salhy, M. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur. J. Clin. Nutr.,  2016, 70(2), 175-181.
[http://dx.doi.org/10.1038/ejcn.2015.191] [PMID:  26603880] 
[54] 
Halmos, E.P.; Power, V.A.; Shepherd, S.J.; Gibson, P.R.; Muir, J.G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology,  2014, 146(1), 67-75.e5.
[http://dx.doi.org/10.1053/j.gastro.2013.09.046] [PMID:  24076059] 
[55] 
Staudacher, H.M.; Lomer, M.C.E.; Louis, P. The low FODMAP diet reduces symptoms in irritable bowel syndrome compared with placebo diet and the microbiota alterations may be prevented by probiotic co-administration:A 2x2 factorial randomised controlled trial. Gastroenterol,  2016, 150(4), S230.
[http://dx.doi.org/10.1016/S0016-5085(16)30842-3] 
[56] 
Pedersen, N.; Ankersen, D.V.; Felding, M.; Wachmann, H.; Végh, Z.; Molzen, L.; Burisch, J.; Andersen, J.R.; Munkholm, P. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J. Gastroenterol.,  2017, 23(18), 3356-3366.
[http://dx.doi.org/10.3748/wjg.v23.i18.3356] [PMID:  28566897] 
[57] 
Guerreiro, M.M.; Santos, Z.; Carolino, E.; Correa, J.; Cravo, M.; Augusto, F.; Chagas, C.; Guerreiro, C.S. Effectiveness of two dietary approaches on the quality of life and gastrointestinal symptoms of individuals with irritable bowel syndrome. J. Clin. Med.,  2020, 9(1), 125.
[http://dx.doi.org/10.3390/jcm9010125] [PMID:  31906563] 
[58] 
Aziz, I.; Trott, N.; Briggs, R. Efficacy of a gluten-free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype. Clin. Gastroenterol. Hepatol.,  2016, 14(5), 696-703.
[59] 
Wahnschaffe, U.; Schulzke, J.D.; Zeitz, M.; Ullrich, R. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol.,  2007, 5(7), 844-850.
[http://dx.doi.org/10.1016/j.cgh.2007.03.021] [PMID:  17553753] 
[60] 
Vazquez-Roque, M.I.; Camilleri, M.; Smyrk, T.; Murray, J.A.; Marietta, E.; O’Neill, J.; Carlson, P.; Lamsam, J.; Janzow, D.; Eckert, D.; Burton, D.; Zinsmeister, A.R. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology,  2013, 144(5), 903-911.e3.
[http://dx.doi.org/10.1053/j.gastro.2013.01.049] [PMID:  23357715] 
[61] 
Biesiekierski, J R.; Peters, S L.; Newnham, E D. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterol,  2013, 145(2), 320-328.
[http://dx.doi.org/10.1053/j.gastro.2013.04.051] 
[62] 
Scarpato, E.; Auricchio, R.; Penagini, F.; Campanozzi, A.; Zuccotti, G.V.; Troncone, R. Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: A systematic review on behalf of the Italian Society of Paediatrics. Ital. J. Pediatr.,  2019, 45(1), 9.
[http://dx.doi.org/10.1186/s13052-019-0606-1] [PMID:  30635010] 
[63] 
Chen, C.C.; Walker, W.A. Probiotics and prebiotics: role in clinical disease states. Adv. Pediatr.,  2005, 52, 77-113.
[http://dx.doi.org/10.1016/j.yapd.2005.03.001] [PMID:  16124337] 
[64] 
Moser, A.M.; Spindelboeck, W.; Halwachs, B.; Strohmaier, H.; Kump, P.; Gorkiewicz, G.; Högenauer, C. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur. J. Nutr.,  2019, 58(7), 2767-2778.
[PMID:  30251020] 
[65] 
Tsuchiya, J.; Barreto, R.; Okura, R.; Kawakita, S.; Fesce, E.; Marotta, F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis.,  2004, 5(4), 169-174.
[http://dx.doi.org/10.1111/j.1443-9573.2004.00176.x] [PMID:  15612887] 
[66] 
Colecchia, A.; Vestito, A.; La Rocca, A.; Pasqui, F.; Nikiforaki, A.; Festi, D. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol.,  2006, 52(4), 349-358.
[PMID:  17108864] 
[67] 
Andriulli, A.; Neri, M.; Loguercio, C.; Terreni, N.; Merla, A.; Cardarella, M.P.; Federico, A.; Chilovi, F.; Milandri, G.L.; De Bona, M.; Cavenati, S.; Gullini, S.; Abbiati, R.; Garbagna, N.; Cerutti, R.; Grossi, E. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: A multicenter, randomized study. J. Clin. Gastroenterol.,  2008, 42(Suppl. 3 Pt 2), S218-S223.
[http://dx.doi.org/10.1097/MCG.0b013e31817fadd6] [PMID:  18685503] 
[68] 
Cappello, C.; Tremolaterra, F.; Pascariello, A.; Ciacci, C.; Iovino, P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int. J. Colorectal Dis.,  2013, 28(3), 349-358.
[http://dx.doi.org/10.1007/s00384-012-1552-1] [PMID:  22885882] 
[69] 
Lee, S.H.; Cho, D.Y.; Lee, S.H.; Han, K.S.; Yang, S.W.; Kim, J.H.; Lee, S.H.; Kim, S.M.; Kim, K.N. A randomized clinical trial of synbiotics in irritable bowel syndrome: dose-dependent effects on gastrointestinal symptoms and fatigue. Korean J. Fam. Med.,  2019, 40(1), 2-8.
[http://dx.doi.org/10.4082/kjfm.17.0064] [PMID:  30360032] 
[70] 
Pedersen, N.; Andersen, N.N.; Végh, Z.; Jensen, L.; Ankersen, D.V.; Felding, M.; Simonsen, M.H.; Burisch, J.; Munkholm, P. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J. Gastroenterol.,  2014, 20(43), 16215-16226.
[http://dx.doi.org/10.3748/wjg.v20.i43.16215] [PMID:  25473176] 
[71] 
Bourdu, S.; Dapoigny, M.; Chapuy, E.; Artigue, F.; Vasson, M.P.; Dechelotte, P.; Bommelaer, G.; Eschalier, A.; Ardid, D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology,  2005, 128(7), 1996-2008.
[http://dx.doi.org/10.1053/j.gastro.2005.03.082] [PMID:  15940632] 
[72] 
Sun, Q.; Jia, Q.; Song, L.; Duan, L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore),  2019, 98(7) ,e14513
[http://dx.doi.org/10.1097/MD.0000000000014513] [PMID:  30762787] 
[73] 
Farup, P.G.; Rudi, K.; Hestad, K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol.,  2016, 16(1), 51.
[http://dx.doi.org/10.1186/s12876-016-0446-z] [PMID:  27121286] 
[74] 
Pryde, S.E.; Duncan, S.H.; Hold, G.L.; Stewart, C.S.; Flint, H.J. The microbiology of butyrate formation in the human colon. FEMS Microbiol. Lett.,  2002, 217(2), 133-139.
[http://dx.doi.org/10.1111/j.1574-6968.2002.tb11467.x] [PMID:  12480096] 
[75] 
Sleiman, S.F.; Basso, M.; Mahishi, L.; Kozikowski, A.P.; Donohoe, M.E.; Langley, B.; Ratan, R.R. Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin. Investig. Drugs,  2009, 18(5), 573-584.
[http://dx.doi.org/10.1517/13543780902810345] [PMID:  19388875] 
[76] 
Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; Takahashi, M.; Fukuda, N.N.; Murakami, S.; Miyauchi, E.; Hino, S.; Atarashi, K.; Onawa, S.; Fujimura, Y.; Lockett, T.; Clarke, J.M.; Topping, D.L.; Tomita, M.; Hori, S.; Ohara, O.; Morita, T.; Koseki, H.; Kikuchi, J.; Honda, K.; Hase, K.; Ohno, H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature,  2013, 504(7480), 446-450.
[http://dx.doi.org/10.1038/nature12721] [PMID:  24226770] 
[77] 
Bordin, M.; D’Atri, F.; Guillemot, L.; Citi, S. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. Mol. Cancer Res.,  2004, 2(12), 692-701.
[PMID:  15634758] 
[78] 
Manrique Vergara, D.; González Sánchez, M.E. Short chain fatty acids (butyric acid) and intestinal diseases. Nutr. Hosp.,  2017, 34(Suppl. 4), 58-61.
[http://dx.doi.org/10.20960/nh.1573] [PMID:  29156934] 
[79] 
Gibson, P.R.; Rosella, O.; Wilson, A.J.; Mariadason, J.M.; Rickard, K.; Byron, K.; Barkla, D.H. Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis,  1999, 20(4), 539-544.
[http://dx.doi.org/10.1093/carcin/20.4.539] [PMID:  10223179] 
[80] 
Kotunia, A.; Woliński, J.; Laubitz, D.; Jurkowska, M.; Romé, V.; Guilloteau, P.; Zabielski, R. Effect of sodium butyrate on the small intestine development in neonatal piglets fed [correction of feed] by artificial sow. J. Physiol. Pharmacol.,  2004, 55(Suppl. 2), 59-68.
[PMID:  15608361] 
[81] 
Banasiewicz, T.; Krokowicz, Ł.; Stojcev, Z.; Kaczmarek, B.F.; Kaczmarek, E.; Maik, J.; Marciniak, R.; Krokowicz, P.; Walkowiak, J.; Drews, M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis.,  2013, 15(2), 204-209.
[http://dx.doi.org/10.1111/j.1463-1318.2012.03152.x] [PMID:  22738315] 
[82] 
Hamer, H.M.; Jonkers, D.; Venema, K.; Vanhoutvin, S.; Troost, F.J.; Brummer, R.J. The role of butyrate on colonic function. Aliment. Pharmacol. Ther.,  2008, 27(2), 104-119.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03562.x] [PMID:  17973645] 
[83] 
Ratajczak, W.; Rył, A.; Mizerski, A.; Walczakiewicz, K.; Sipak, O.; Laszczyńska, M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim. Pol.,  2019, 66(1), 1-12.
[http://dx.doi.org/10.18388/abp.2018_2648] [PMID:  30831575] 
[84] 
Chen, T.; Noto, D.; Hoshino, Y.; Mizuno, M.; Miyake, S. Butyrate suppresses demyelination and enhances remyelination. J. Neuroinflammation,  2019, 16(1), 165.
[http://dx.doi.org/10.1186/s12974-019-1552-y] [PMID:  31399117] 
[85] 
Tontini, G.E.; Stella, A.; Campieri, M.; Vecchi, M. Association among the use of probiotics and butyrate in Irritable bowel syndrome. Abstr in National meeting of Gastroenterology
	and digestive endoscopy,; Rome,, 2009.
[86] 
Russo, R.; Cristiano, C.; Avagliano, C.; De Caro, C.; La Rana, G.; Raso, G.M.; Canani, R.B.; Meli, R.; Calignano, A. Gut-brain axis: role of lipids in the regulation of inflammation, pain and CNS diseases. Curr. Med. Chem.,  2018, 25(32), 3930-3952.
[http://dx.doi.org/10.2174/0929867324666170216113756] [PMID:  28215162] 
[87] 
Storr, M.A.; Sharkey, K.A. The endocannabinoid system and gut-brain signalling. Curr. Opin. Pharmacol.,  2007, 7(6), 575-582.
[http://dx.doi.org/10.1016/j.coph.2007.08.008] [PMID:  17904903] 
[88] 
Pacher, P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev.,  2006, 58(3), 389-462.
[http://dx.doi.org/10.1124/pr.58.3.2] [PMID:  16968947] 
[89] 
Fichna, J.; Wood, J.T.; Papanastasiou, M.; Vadivel, S.K.; Oprocha, P.; Sałaga, M.; Sobczak, M.; Mokrowiecka, A.; Cygankiewicz, A.I.; Zakrzewski, P.K.; Małecka-Panas, E.; Krajewska, W.M.; Kościelniak, P.; Makriyannis, A.; Storr, M.A. Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: A pilot study. PLoS One,  2013, 8(12) ,e85073
[http://dx.doi.org/10.1371/journal.pone.0085073] [PMID:  24386448] 
[90] 
Brugnatelli, V.; Turco, F.; Freo, U.; Zanette, G. Irritable bowel syndrome: manipulating the endocannabinoid system as first-line treatment. Front. Neurosci.,  2020, 14, 371.
[http://dx.doi.org/10.3389/fnins.2020.00371] [PMID:  32372912] 
[91] 
Skaper, S.D.; Facci, L.; Giusti, P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol.,  2013, 48(2), 340-352.
[http://dx.doi.org/10.1007/s12035-013-8487-6] [PMID:  23813098] 
[92] 
Cordaro, M.; Scuto, M.; Siracusa, R.; D’amico, R.; Filippo Peritore, A.; Gugliandolo, E.; Fusco, R.; Crupi, R.; Impellizzeri, D.; Pozzebon, M.; Alfonsi, D.; Mattei, N.; Marcolongo, G.; Evangelista, M.; Cuzzocrea, S.; Di Paola, R. Effect of N-palmitoylethanolamine-oxazoline on comorbid neuropsychiatric disturbance associated with inflammatory bowel disease. FASEB J.,  2020, 34(3), 4085-4106.
[http://dx.doi.org/10.1096/fj.201901584RR] [PMID:  31950563] 
[93] 
Barbara, G.; Cremon, C.; Bellacosa, L. 714 randomized placebo-controlled multicenter study on the effect of palmitoyl-ethanolamide and polydatin on immune activation in patients with irritable bowel syndrome. Gastroenterology,  2014, 146, S-124.
[http://dx.doi.org/10.1016/S0016-5085(14)60446-7] 
[94] 
Cremon, C.; Stanghellini, V.; Barbaro, M.R.; Cogliandro, R.F.; Bellacosa, L.; Santos, J.; Vicario, M.; Pigrau, M.; Alonso Cotoner, C.; Lobo, B.; Azpiroz, F.; Bruley des Varannes, S.; Neunlist, M.; DeFilippis, D.; Iuvone, T.; Petrosino, S.; Di Marzo, V.; Barbara, G. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment. Pharmacol. Ther.,  2017, 45(7), 909-922.
[http://dx.doi.org/10.1111/apt.13958] [PMID:  28164346] 
[95] 
Impellizzeri, D.; Bruschetta, G.; Cordaro, M.; Crupi, R.; Siracusa, R.; Esposito, E.; Cuzzocrea, S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J. Neuroinflammation,  2014, 11, 136.
[http://dx.doi.org/10.1186/s12974-014-0136-0] [PMID:  25164769] 
[96] 
Fasano, A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol. Rev.,  2011, 91(1), 151-175.
[http://dx.doi.org/10.1152/physrev.00003.2008] [PMID:  21248165] 
[97] 
Menchetti, L.; Traina, G.; Tomasello, G.; Casagrande-Proietti, P.; Leonardi, L.; Barbato, O.; Brecchia, G. Potential benefits of colostrum in gastrointestinal diseases. Front. Biosci. (Schol. Ed.),  2016, 8, 331-351.
[http://dx.doi.org/10.2741/s467] [PMID:  27100711] 
[98] 
Hałasa, M.; Maciejewska, D.; Baśkiewicz-Hałasa, M.; Machaliński, B.; Safranow, K.; Stachowska, E. Oral supplementation with bovine colostrum decreases intestinal permeability and stool concentrations of zonulin in athletes. Nutrients,  2017, 9(4), 370.
[http://dx.doi.org/10.3390/nu9040370] [PMID:  28397754] 
[99] 
Fasano, A. Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall. Am. J. Pathol.,  2008, 173(5), 1243-1252.
[http://dx.doi.org/10.2353/ajpath.2008.080192] [PMID:  18832585] 
[100] 
Playford, R.J.; MacDonald, C.E.; Calnan, D.P.; Floyd, D.N.; Podas, T.; Johnson, W.; Wicks, A.C.; Bashir, O.; Marchbank, T. Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clin. Sci. (Lond.),  2001, 100(6), 627-633.
[http://dx.doi.org/10.1042/CS20010015] [PMID:  11352778] 
[101] 
Marchbank, T.; Davison, G.; Oakes, J.R.; Ghatei, M.A.; Patterson, M.; Moyer, M.P.; Playford, R.J. The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. Am. J. Physiol. Gastrointest. Liver Physiol.,  2011, 300(3), G477-G484.
[http://dx.doi.org/10.1152/ajpgi.00281.2010] [PMID:  21148400] 
[102] 
Velikova, T.; Tumangelova-Yuzeir, K.; Georgieva, R.; Ivanova-Todorova, E.; Karaivanova, E.; Nakov, V.; Nakov, R.; Kyurkchiev, D. Lactobacilli supplemented with larch arabinogalactan and colostrum stimulates an immune response towards peripheral NK activation and gut tolerance. Nutrients,  2020, 12(6), 1706.
[http://dx.doi.org/10.3390/nu12061706] [PMID:  32517330] 
[103] 
Wikoff, W.R.; Anfora, A.T.; Liu, J.; Schultz, P.G.; Lesley, S.A.; Peters, E.C.; Siuzdak, G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA,  2009, 106(10), 3698-3703.
[http://dx.doi.org/10.1073/pnas.0812874106] [PMID:  19234110] 
[104] 
Rousseaux, C.; Thuru, X.; Gelot, A.; Barnich, N.; Neut, C.; Dubuquoy, L.; Dubuquoy, C.; Merour, E.; Geboes, K.; Chamaillard, M.; Ouwehand, A.; Leyer, G.; Carcano, D.; Colombel, J.F.; Ardid, D.; Desreumaux, P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med.,  2007, 13(1), 35-37.
[http://dx.doi.org/10.1038/nm1521] [PMID:  17159985] 
[105] 
Quigley, E.M. Probiotics in irritable bowel syndrome: the science and the evidence. J. Clin. Gastroenterol.,  2015, 49(Suppl. 1), S60-S64.
[http://dx.doi.org/10.1097/MCG.0000000000000348] [PMID:  26447967] 
[106] 
National Institute for Health and Care Excellence (NICE).. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care., 2015.
[107] 
Hardy, H.; Harris, J.; Lyon, E.; Beal, J.; Foey, A.D. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients,  2013, 5(6), 1869-1912.
[http://dx.doi.org/10.3390/nu5061869] [PMID:  23760057] 
[108] 
Portincasa, P.; Lembo, A.; de Bari, O.; Di Palo, D.M.; Maggio, A.; Cataldo, I.; Calamita, G. The role of dietary approach in irritable bowel syndrome. Curr. Med. Chem.,  2019, 26(19), 3512-3520.
[http://dx.doi.org/10.2174/0929867324666170428102451] [PMID:  28462704] 
Rights & Permissions Print Cite
Article Metrics
16
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0929867328666210917115255	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X
Current Medicinal Chemistry

Why Use Nutraceutical Strategies for the Irritable Bowel Syndrome?

Abstract Play Pause

Related Journals

Related Books

Abstract
